Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracer (18F-Fluciclovine) Using Amino Acid Metabolism
| Property | Description |
|---|---|
| Indication | Imaging in men with suspected prostate cancer recurrence based on elevated blood level of prostate-specific antigen after treatment |
| Administered dose for adults | 370 MBq (10 mCi) |
| Injection route | Intravenous |
| Injection-to-imaging time | 4–10 min |
| Normal biodistribution | Pancreas, liver, bone marrow, muscle |